Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Clinical Oncology

• Publication date

  1999-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1999.17.2.501PMID 10080591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.

  1997cited by this paper
• Experience with independent radiological review during a topotecan trial in ovarian cancer.

  1997cited by this paper
• Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.

  1997cited by this paper
• Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.

  1997cited by this paper
• Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

  1996cited by this paper
• CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?

  1996cited by this paper
• Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study.

  1996cited by this paper
• Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.

  1995cited by this paper
• Technical evaluation of three second generation CA 125 assays.

  1994cited by this paper
• Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.

  1994cited by this paper
• European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

  1994cited by this paper
• CA 125 half-life in ovarian cancer: a multivariate survival analysis.

  1993cited by this paper
• The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer

  1992cited by this paper
• The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.

  1990cited by this paper
• CA‐125 Values Predictive of Clinical Response during Second‐Line Chemotherapy for Epithelial Ovarian Cancer

  1989cited by this paper
• Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.

  1989cited by this paper
• The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary.

  1989cited by this paper
• The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.

  1988cited by this paper
• Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.

  1988cited by this paper
• CA 125 for the monitoring of ovarian carcinoma during primary therapy

  1987cited by this paper
• Evaluation of serum CA 125 levels in the monitoring of ovarian cancer

  1987cited by this paper
• The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

  1986cited by this paper
• Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.

  1984cited by this paper
• A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

  1983cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper

• What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China

  2022cites this paper
• Malignant diseases of the ovary, fallopian tube, and peritoneum

  2022cites this paper
• Pancreatic and Ovarian Cancer Biomarkers

  2019cites this paper
• CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review

  2016cites this paper
• COMPARISON OF SERUM HE4 AND CA125 LEVELS IN THE DETECTION OF RECURRENT OVARIAN CANCER

  2016cites this paper
• CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients

  2015cites this paper
• Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging.

  2015cites this paper
• 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

  2014cites this paper
• Pancreatic and ovarian cancer biomarkers

  2014cites this paper
• MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

  2014cites this paper
• Uso de marcadores tumorales en cáncer de testículo, próstata, colorrectal, mama y ovario

  2013cites this paper
• MUC16, alias CA125 and ovarian cancer

  2013cites this paper
• Mucins and Cancer

  2013cites this paper
• Pursuit of Optimum Outcomes in Ovarian Cancer

  2012cites this paper
• Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

  2012cites this paper
• Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer

  2012cites this paper
• Pharmaceutical Management of Ovarian Cancer

  2012cites this paper
• Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.

  2012cites this paper
• Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

  2012cites this paper
• Polymorphism and expression of IL-10 in serum and ascites from patients with advanced ovarian cancer

  2011cites this paper
• Ovarian cancer: the duplicity of CA125 measurement

  2010cites this paper
• The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.

  2010cites this paper
• Effective Incorporation of Biomarkers into Phase II Trials

  2009cites this paper
• The expressions of bHLH gene HES1 and HES5 in advanced ovarian serous adenocarcinomas and their prognostic significance: a retrospective clinical study

  2009cites this paper
• Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer

  2009cites this paper
• Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer.

  2009cites this paper
• Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?

  2009cites this paper
• CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

  2009cites this paper
• REVIEW OF CARCINOMA ANTIGEN 125 (CA 125) AS A MARKER OF DISEASE PROGRESSION OR RECURRENCE IN CLINICAL TRIALS

  2009cites this paper
• A Phase II Trial of Fixed-Dosed Rate Gemcitabine in Platinum-Resistant Ovarian Cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial

  2008cites this paper
• [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].

  2008cites this paper
• Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer.

  2008cites this paper
• New Tumor Biomarkers

  2008cites this paper
• Ovaries and Fallopian Tubes

  2008cites this paper
• Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.

  2008cites this paper
• Role of 18 F-fluorodeoxyglucose PET/CT in Recurrent Ovary Cancer

  2008cites this paper
• Detection of circulating cancer cells in lung cancer patients with a panel of marker genes.

  2008cites this paper
• Understanding tumour markers

  2008cites this paper
• National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

  2008cites this paper
• Lack of reliability of CA125 response criteria with anti‐VEGF molecularly targeted therapy

  2008cites this paper
• Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.

  2008cites this paper
• Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

  2008cites this paper
• Targeted Therapy in Epithelial Ovarian Cancer

  2008cites this paper
• Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen

  2007cites this paper
• Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.

  2007cites this paper
• The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.

  2007cites this paper
• Prognostic value of Ca 125 levels during primary therapy.

  2007cites this paper
• Modulation of CA-125 tumor marker shedding in ovarian cancer cells by erlotinib or cetuximab.

  2007cites this paper
• Oral Thalidomide as Palliative Chemotherapy in Women with Advanced Ovarian Cancer

  2007cites this paper
• Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.

  2007cites this paper
• Neoplastic Diseases of the Ovary

  2007cites this paper
• The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel

  2007cites this paper
• CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study.

  2006cites this paper
• Ovarian Cancer Patients Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Early Changes in CA 125 After Treatment with Pegylated Liposomal

  2006cites this paper
• Early Changes in CA 125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients

  2006cites this paper
• National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Ovarian Cancer

  2006cites this paper
• Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer

  2006cites this paper
• Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.

  2006cites this paper
• Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

  2006cites this paper
• Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

  2006cites this paper
• Positron Emission Tomography using F-18 Fluorodeoxyglucose for Monitoring Neoadjuvant Chemotherapy in Advanced Stage Ovarian Cancer

  2006cites this paper
• Biochemical recurrent ovarian cancer: CA 125 elevation without symptoms or clinical evidence of disease. What is the optimal management?

  2006cites this paper
• Progressive epithelial ovarian carcinoma

  2006cites this paper
• Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

  2005cites this paper
• Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel.

  2005cites this paper
• The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma

  2005cites this paper
• Klinische Ergebnisse von Patientinnen mit primärem und sekundärem epithelialem Ovarialkarzinom im Krankenhaus im Friedrichshain von 1992 bis 1998

  2005cites this paper
• The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.

  2005cites this paper
• Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.

  2005cites this paper
• Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

  2004cites this paper
• Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.

  2004cites this paper
• Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer

  2004cites this paper
• Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.

  2004cites this paper
• Markov-Modellierung zum Einsatz von Platinanaloga und Paclitaxel als First-line-Chemotherapie sowie von Topotecan und liposomalem Doxorubicin als Second-line-Chemotherapie beim epithelialen Ovarialkarzinom

  2004cites this paper
• Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer.

  2004cites this paper
• Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

  2004cites this paper
• CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

  2004cites this paper
• Can we now agree to use the same definition to measure response according to CA-125?

  2004cites this paper
• Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

  2004cites this paper
• The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.

  2004cites this paper
• Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum

  2004cites this paper
• "CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA?"

  2004cites this paper
• Distinct subtypes of serous ovarian carcinoma identified by p53 determination.

  2003cites this paper
• Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.

  2003cites this paper
• IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro.

  2003cites this paper
• Specific keynote: clinical trial design problems in ovarian cancer.

  2003cites this paper
• The myth of measurable disease in ovarian cancer.

  2003cites this paper
• Limitations to the use of the CA-125 antigen level in ovarian cancer

  2003cites this paper
• Ovarian Cancer – Diagnostical and Therapeutical Dilema in Oncological Gynecology

  2003cites this paper
• Serum tumor markers.

  2003cites this paper
• CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer

  2003cites this paper
• IFN-γ Induces Apoptosis in Ovarian Cancer Cells in Vivo and in Vitro

  2003cites this paper
• Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.

  2003cites this paper
• Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium.

  2003cites this paper
• Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

  2003cites this paper
• Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.

  2003cites this paper
• Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma.

  2002cites this paper
• A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.

  2002cites this paper
• Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

  2002cites this paper
• A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer

  2002cites this paper